Evidence map›Paper›PMID 41654576›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Balancing innovation and accessibility in infection imaging: lessons from the [

Océane Mesnilgrante, Typhanie Ladrière, Noémie Allouche, Laura Aussage, Frédérique Grandhomme, Stéphane Allouche, Damien Peyronnet, Jonathan Vigne

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Océane MesnilgranteUNICAEN Department of Nuclear Medicine, CHU Caen Normandie, Normandie Université, Avenue de La Côte de Nacre, CS 30001, 14000, Caen, France.
Typhanie LadrièreUNICAEN Department of Nuclear Medicine, CHU Caen Normandie, Normandie Université, Avenue de La Côte de Nacre, CS 30001, 14000, Caen, France.
Noémie AlloucheUNICAEN Department of Nuclear Medicine, CHU Caen Normandie, Normandie Université, Avenue de La Côte de Nacre, CS 30001, 14000, Caen, France.
Laura AussageUNICAEN Department of Nuclear Medicine, CHU Caen Normandie, Normandie Université, Avenue de La Côte de Nacre, CS 30001, 14000, Caen, France.
Frédérique GrandhommeUNICAEN Department of Biochemistry, CHU Caen Normandie, Normandie Université, 14000, Caen, France.
Stéphane AlloucheUNICAEN Department of Biochemistry, CHU Caen Normandie, Normandie Université, 14000, Caen, France.
Damien PeyronnetUNICAEN Department of Nuclear Medicine, CHU Caen Normandie, Normandie Université, Avenue de La Côte de Nacre, CS 30001, 14000, Caen, France.
Jonathan VigneUNICAEN Department of Nuclear Medicine, CHU Caen Normandie, Normandie Université, Avenue de La Côte de Nacre, CS 30001, 14000, Caen, France. vigne-jo@chu-caen.fr.ORCID http://orcid.org/0000-0002-6575-9224

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfection imaging plays a crucial role in clinical decision making, guiding antibiotic therapy and surgical management. Nuclear medicine offers molecular level approaches using three main techniques: [ MAIN BODY: In recent years, significant regulatory changes in the European framework for in vitro diagnostics (IVDR 2017/746) have coincided with the withdrawal of the quantitative HAMA enzyme-linked immunosorbent assay from the market and its replacement with a qualitative rapid test. Although this shift aimed to streamline in vitro testing procedures, it has complicated the interpretation of HAMA results and raised concerns about diagnostic accessibility. In some centres, an increase in positive results has been observed with rapid tests, suggesting that patients may be inappropriately excluded from [

conclusionThis debate argues that restoring accessibility to [

Indexed as

[18F]FDG PET/CT[99mTc]Tc-besilesomabHuman anti-mouse antibodies (HAMA)Infection imagingRadio-immunodiagnosticRadiopharmaceuticals

Identifiers

PMID41654576
PMCPMC13000082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.